Treatment and prevention of bone loss using resolvins

Abstract

The invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolving. In particular, the inventive methods may be useful for treating or preventing conditions associated with bone degradation, deterioration or degeneration such as periodontal disease, osteoarthritis, and metastatic bone disease and osteolytic bone disease. Pharmaceutical compositions and kits comprising at least one resolving are also provided that can be used to performed the inventive methods.

1 - 17 . (canceled) 
     
     
         18 . A pharmaceutical composition comprising at least one resolvin, at least one therapeutic agent that promotes bone growth or inhibits bone resorption, and at least one pharmaceutically acceptable carrier or excipient. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the therapeutic agent that promotes bone growth or inhibits bone resorption is selected from the group consisting of bone morphogenetic factors, anti-resorptive agents, osteogenic factors, cartilage-derived morphogenetic proteins, growth hormones, estrogens, bisphosphonates, statins, differentiating factors, growth factors, connective tissue activating peptides (CTAPs), minerals, vitamins, hormones, prostaglandins, inhibitors of 15-lipoxygenase, dexamethasone, bone morphogenic proteins, progestins, estrone, estriol, 17α-ethynyl estradiol, 17β-ethynyl estradiol, SB242784, polyphosphonates, and combinations thereof. 
     
     
         20 . The pharmaceutical composition of  claim 18 , wherein said at least one resolvin is selected from the group consisting of members of the Resolvin E series, members of the Resolvin D series, and combinations thereof. 
     
     
         21 . The pharmaceutical composition of  claim 20 , wherein said at least one resolvin is selected from the group consisting of di-hydroxy members of the Resolvin E series, di-hydroxy members of the Resolvin D series, tri-hydroxy members of the Resolvin E series, tri-hydroxy members of the Resolvin D series, and combinations thereof. 
     
     
         22 . The pharmaceutical composition of  claim 20 , wherein said at least one resolvin comprises Resolvin E1, Resolvin D1, or Resolvin D2. 
     
     
         23 . The pharmaceutical composition of  claim 18 , wherein said composition is formulated to be administered topically. 
     
     
         24 . The pharmaceutical composition of  claim 23 , wherein said composition is formulated to be topically administered to a subject that is susceptible to or is suffering from a bone condition associated with bone loss. 
     
     
         25 . The pharmaceutical composition of  claim 24 , wherein said bone condition is selected from the group consisting of periodontal disease, bone fracture, bone deficiency, metastatic bone disease, osteoarthritis, and osteolytic bone disease. 
     
     
         26 . The pharmaceutical composition of  claim 25 , wherein periodontal disease is gingivitis or periodontitis. 
     
     
         27 . The pharmaceutical composition of  claim 23 , wherein said composition is formulated to be administered topically to the subject's oral cavity. 
     
     
         28 . The pharmaceutical composition of  claim 27 , wherein said composition is formulated as a preparation selected from the group consisting of solution, suspension, dispersion, ointment, cream, gel, toothpaste, tooth powder, lozenge, salve, chewing gum, aerosol, mouth spray, pastille, sachet, mouthwash, toothpick, tablet, capsule, and dental floss. 
     
     
         29 . The pharmaceutical composition of  claim 18 , wherein said composition further comprises at least one additional therapeutic agent selected from the group consisting of analgesics, anesthetics, antimicrobial agents, antibacterial agents, antiviral agents, antifungal agents, antibiotics, anti-inflammatory agents, antioxidants, antiseptic agents, immunostimulating agents, antiprotozoan agents, and combinations thereof. 
     
     
         30 . The pharmaceutical composition of  claim 18 , wherein administration of said composition to a subject in need thereof results in one or more of: prevention of bone deterioration, prevention of bone degradation, prevention of bone degeneration, prevention of loss of bone mass, prevention of loss of bone density, stabilization of bone deterioration, stabilization of bone degradation, stabilization of bone degeneration, stabilization of loss of bone mass, stabilization of loss of bone density, decrease of bone deterioration, decrease of bone degradation, decrease of bone degeneration, decrease of loss of bone mass, decrease of loss of bone density, increase of bone mass, increase of bone density, and combinations thereof. 
     
     
         31 - 46 . (canceled)